Pharmaceuticals, Biotechnology & Life Sciences

NovaBridge insider buying signals confidence amid a 28% decline: senior VP Xu Cong Claire’s purchase may hint at upcoming clinical milestones and potential upside.

Hyperion DeFi insider buys boost confidence as Phase II results show promising visual‑acuity gains for nAMD therapy, hinting at future FDA approval and market impact.

Hecht Beth’s steady insider sales at Xeris Biopharma signal a strategic realignment and possible undervaluation—watch how pipeline prospects may drive a rally or decline.

Explore GRAIL’s insider trades, Galleri’s market rollout, and the biopharma landscape—insights into strategy, pricing, and investor confidence.

CRISPR Therapeutics insider RSU purchase signals long‑term confidence in gene‑editing platform, sparking a stock rally and heightened investor buzz.

Insider sales at Vir Biotechnology show routine portfolio moves, not a warning—see how recent trades and pipeline prospects influence investor sentiment and market value.

Halozyme insider sale analysis: a routine portfolio move amid steady bispecific antibody growth and mid‑cap stability.

4D Molecular Therapeutics insider sale: CEO David Kirn sells 1,922 shares via a 10(b)(5)(1) plan at $10.02—showing confidence while keeping long‑term stake.

Insider buying by CRL executives signals confidence in its automation‑driven growth, robust contract pipeline, and value‑based reimbursement strategy amid a volatile valuation.

Insider buys and RSUs signal confidence in Acadia’s CNS pipeline, suggesting a 2026‑2027 upside as Parkinson’s and schizophrenia trials mature.